Breast Cancer Clinical Trial
Official title:
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Verified date | January 2018 |
Source | Corcept Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a study to assess the safety of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors, and determine preliminary efficacy of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable Triple Negative Breast Cancer (TNBC). The structure for the study is a single arm, non-randomized, open-label, multicenter trial with no control group. The study will be conducted at up to 11 sites, with up to 40 evaluable patients
Status | Completed |
Enrollment | 37 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Informed consent given prior to study-specific screening procedures 2. = 18 years old Part 2, dose expansion: 1. Diagnosis of TNBC: < 1% cells positive for ER/progesterone receptor, and HER2 IHC score of 0 or 1, or FISH HER2+ ratio of less than 1.8; patients with low ER IHC (> 1% but < 10% cells positive), but negative by genomic assay are eligible 2. Inoperable metastatic or locally advanced unresectable disease 3. Patients should have received a minimum of one, and up to five prior chemotherapy regimens 4. Must have submitted a diagnostic FFPE tumor tissue sample to confirm tumor GR positivity. Tumor tissue may be from primary or metastatic lesion. In the absence of sufficient tissue to complete IHC, a tumor biopsy will be required. 5. Tumor must be glucocorticoid receptor positive TNBC (=10% positive cells by IHC of tumor biopsy) 6. Must have measurable disease (RECIST v1.1) in at least one lesion not previously irradiated unless documented evidence of progression 7. Patients with treated, stable brain metastases eligible providing treatment was =4 weeks prior to initiation of study drug, and baseline CT or MRI negative for new brain metastases. Must not require therapy with corticosteroids. 8. ECOG performance status 0 or 1 9. Must have adequate bone marrow and renal/hepatic function at the screening visit (=7 days preceding the lab assessment): i. ANC = 1,500/mm3, without G-CSF ii. Platelets = 100,000/mm3, without transfusion iii. Hemoglobin = 9 g/dL, without transfusion support iv. AST or ALT = 3 × ULN v. Total serum bilirubin = 1.5 times ULN vi. Serum creatinine = ULN vii. Potassium and magnesium levels within normal limits. If below the lower limit of normal, must have levels corrected by supplementation prior to starting study drug. viii. albumin > 3.0 g/dL 10. PT/aPIT = 1.5 x ULN 11. Disease-free period of > 3 years from any other previous malignancies, excluding curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. 12. Female patients of childbearing potential must have a negative serum pregnancy test. Sexually active patients must be willing to use non-hormonal contraception, including condom use by male partner, and barrier method by the female partner during the treatment period and for at least 3 months after the last dose of the study drug. Females considered not of childbearing potential include those who have been in menopause > 2 years, or are surgically sterile (status post tubal ligation or hysterectomy). 13. Must be able and willing to comply with the study visit schedule and study procedures. 14. Able to take oral medications Exclusion Criteria: 1. Systemic cytotoxic therapies or radiotherapy =14 days prior to day 1 cycle 1 2. Major surgery within 4 weeks, or minor surgery within 2 weeks prior to day 1 of cycle 1 3. Endometrial bleeding 4. For two weeks prior to day 1 cycle 1, administration of specified cytochrome P450 3A (CYP3A) inducers 5. Patients who are taking simvastatin or lovastatin. Patients should be switched to alternative therapies a minimum of 2 weeks before starting study drug 6. Patients who have been treated with an investigational agent <21 days prior to day 1 of cycle 1 7. Concomitant use of biological agents including growth factors. Exception: 3- to 6-patient breast cancer cohort enrolled to explore the use of prophylactic growth-factor support of a 1.4 mg/m2 dose of eribulin. 8. Patients who require treatment with systemic corticosteroids for serious medical conditions or illnesses (e.g. immunosuppression after organ transplantation) 9. History of significant cardiac disease. Includes second/third degree heart block; significant ischemic heart disease; mean QTc interval > 480 msec prior to study start; poorly controlled hypertension; congestive heart failure of NYHA Class II or worse 10. Pregnant or breast-feeding 11. Any other significant co-morbid conditions that would impair study participation or cooperation 12. In Part 2, unable or unwilling to consent to provision of tumor tissue for GR assay |
Country | Name | City | State |
---|---|---|---|
United States | Winship Cancer Institute, Emory University | Atlanta | Georgia |
United States | Rita Nanda, MD | Chicago | Illinois |
United States | Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas |
United States | Virginia Cancer Specialists | Fairfax | Virginia |
United States | St. Luke's Cancer Institute | Kansas City | Missouri |
United States | Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada |
United States | Quest Research | Royal Oaks | Michigan |
United States | Cancer Care Centers of South Texas | San Antonio | Texas |
United States | H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida |
United States | ACRC/Arizona Clinical Research Center Inc. | Tucson | Arizona |
United States | Texas Oncology - Tyler | Tyler | Texas |
Lead Sponsor | Collaborator |
---|---|
Corcept Therapeutics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the MTD and recommended Phase 2 dose (RP2D) of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors. | In the dose escalation phase: MTD time frame is within 28 days of first dose (Cycle 1) | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |